Cloud for AI/ML & Modern Data Science Header Image

 





Cloud for AI/ML & Modern Data Science
Optimize Cloud Performance, Cost, and Governance for AI-Driven R&D
5/19/2027 - May 20, 2027 ALL TIMES EDT
As AI/ML, advanced analytics, and data-intensive science place new demands on pharmaceutical and biotech R&D, cloud infrastructure must deliver the compute power, scalability, flexibility, and security these workloads require. Organizations must also determine how best to use public, private, hybrid, and multi-cloud environments while balancing cost, performance, security, and regulatory requirements. The Cloud for AI/ML & Modern Data Science track explores how life sciences organizations are designing and optimizing cloud environments for modern R&D. Through case studies and best practices, the track examines cloud strategies for AI/ML and scientific computing, GPU and HPC workloads, hybrid and multi-cloud architectures, secure and sovereign cloud, workload orchestration, cost optimization, and emerging cloud technologies.
Preliminary Agenda

STRATEGY, GOVERNANCE, AND REGULATED AI IN THE CLOUD

Reasoning under Uncertainty: Technology Strategies for the Age of AI

Photo of Chris Dwan, Fractional CIO, Triveni Bio , Independent Consultant , Dwan, LLC
Chris Dwan, Fractional CIO, Triveni Bio , Independent Consultant , Dwan, LLC

Natasha A. Sahr, PhD, Senior Director, Biostatistics, AI & Machine Learning Biometrics, Solid Biosciences, Inc. , Sr Dir Biostatistics , AI & Machine Learning Biometrics , Solid Biosciences Inc

Photo of Kejie Li, PhD, Vice President & Head of Data Science, Triveni Bio , VP , Data Science , Triveni Bio Inc
Kejie Li, PhD, Vice President & Head of Data Science, Triveni Bio , VP , Data Science , Triveni Bio Inc

PLATFORMS AND COMPUTE FOR DESIGN AT SCALE

Data Platforms for AI-Augmented Experiment Design

Photo of Adam Mendez, Senior Director, Data & Cloud Platforms, Flagship Pioneering , Senior Director, Data & Cloud Platforms , Data & Cloud Platforms , Flagship Pioneering
Adam Mendez, Senior Director, Data & Cloud Platforms, Flagship Pioneering , Senior Director, Data & Cloud Platforms , Data & Cloud Platforms , Flagship Pioneering
Photo of Tejasvi Srigiriraju, Full Stack Developer, AbbVie , Full Stack Developer , AbbVie
Tejasvi Srigiriraju, Full Stack Developer, AbbVie , Full Stack Developer , AbbVie

Evolving a Function-First Data Platform for Generative Protein Design

Photo of Adam Kraut, Director, Research Informatics and Data Architecture, Metaphore Bio , Director Research Informatics , Infrastructure & Cloud Architecture , Metaphore
Adam Kraut, Director, Research Informatics and Data Architecture, Metaphore Bio , Director Research Informatics , Infrastructure & Cloud Architecture , Metaphore

Metaphore Bio’s function-first approach to generative protein design depends on data infrastructure that connects computational design with experimental validation. Building on our platform architecture, this presentation examines its evolution to support agentic protein design campaigns and wet lab validation, with a focus on cost efficiency and architectural transitions. Concrete examples will illustrate how platform requirements evolve as programs advance through discovery toward IND-enabling studies.

THE STATE OF DIGITAL R&D: AI, EMERGING TECHNOLOGIES, AND INDUSTRY PERSPECTIVES

Trends from the Trenches: Perspectives from the Field

Photo of Eleanor A. Howe, PhD, Founder & CEO, Diamond Age Data Science , Founder & CEO , Diamond Age Data Science
Eleanor A. Howe, PhD, Founder & CEO, Diamond Age Data Science , Founder & CEO , Diamond Age Data Science

THE FUTURE OF SCIENTIFIC DISCOVERY: HUMAN JUDGMENT AND AI-DRIVEN R&D

PLENARY KEYNOTE PRESENTATION: When AI Becomes the Scientist's Partner: Human Judgment and the Future of R&D

Photo of Santha Ramakrishnan, PhD, Vice President, Head, R&D Data Strategy and Governance, Bayer Pharmaceuticals , VP, Head, R&D Data Strategy and Governance , Bayer Pharmaceuticals
Santha Ramakrishnan, PhD, Vice President, Head, R&D Data Strategy and Governance, Bayer Pharmaceuticals , VP, Head, R&D Data Strategy and Governance , Bayer Pharmaceuticals
Photo of Anu Sharma, Senior Principal Scientist/Senior Director, MRL BARDS Epidemiology RWE Capabilities and Analytics, Merck & Co., Inc. , Senior Principal Scientist and Senior Director , MRL BARDS Epidemiology RWE Capabilities and Analytics , Merck
Anu Sharma, Senior Principal Scientist/Senior Director, MRL BARDS Epidemiology RWE Capabilities and Analytics, Merck & Co., Inc. , Senior Principal Scientist and Senior Director , MRL BARDS Epidemiology RWE Capabilities and Analytics , Merck

As AI agents evolve from research assistants into active partners in scientific discovery, what becomes the scientist's unique contribution? How can researchers challenge AI-generated conclusions, recognize overlooked opportunities, and preserve scientific judgment? Senior biopharma leaders will explore how human-AI collaboration is transforming R&D decision-making, operating models, workforce capabilities, and accountability, while examining the leadership and organizational strategies needed to harness increasingly autonomous AI systems for scientific innovation and patient impact.

CHANGING THE TRAJECTORY OF DISEASE: FROM PREDICTION TO INTERVENTION

PLENARY KEYNOTE PRESENTATION: Can we Predict Disease before it Happens? Mapping and Redirecting Biological Trajectories

Photo of John Quackenbush, PhD, Professor of Pediatrics and Human Genetics, University of Chicago; Professor Emeritus of Computational Biology and Bioinformatics, Harvard T.H. Chan School of Public Health , Professor of Pediatrics and Human Genetics , University of Chicago
John Quackenbush, PhD, Professor of Pediatrics and Human Genetics, University of Chicago; Professor Emeritus of Computational Biology and Bioinformatics, Harvard T.H. Chan School of Public Health , Professor of Pediatrics and Human Genetics , University of Chicago

Biomedical research has generated increasingly large, rich, and multidimensional datasets, yet we still often study disease by dividing people into discrete categories: healthy or diseased, responder or non-responder, case or control. Biology, however, does not operate in static states. Disease develops along a continuum, shaped by changing regulatory programs and influenced by aging, biological sex, genetics, epigenetics, and environmental exposures.

As our data and computational capabilities advance, an important opportunity is emerging: moving beyond cataloging molecular differences to reconstructing how biological systems change over time. Gene regulatory networks, pseudo-time modeling, and change-point analysis can help identify critical regulatory switches that move a biological system from one state to another and reveal drivers of disease that may be missed when we focus only on individual mutations, genes, or biomarkers.

These approaches are beginning to provide insight into why individuals exposed to similar risks can follow very different disease trajectories, why biological sex can influence disease susceptibility and treatment response, and how aging may reshape the path toward chronic disease. Identifying these transition points may also uncover new therapeutic targets and opportunities to intervene before disease becomes firmly established.

The ultimate vision is a predictive theoretical biology: The ability to understand where an individual is biologically, anticipate where that trajectory may lead, and identify opportunities to redirect it. Moving from describing disease after it occurs toward predicting and ultimately altering its course could transform how we approach target discovery, therapeutic development, and precision medicine.

PLENARY KEYNOTE PRESENTATION: From Data to the Individual: Connecting the Pieces to Deliver Precision Medicine

Photo of Elizabeth Worthey, PhD, Director, Center for Computational Genomics & Data, University of Alabama Birmingham , Director , Ctr for Computational Genomics & Data , Univ Of Alabama Birmingham
Elizabeth Worthey, PhD, Director, Center for Computational Genomics & Data, University of Alabama Birmingham , Director , Ctr for Computational Genomics & Data , Univ Of Alabama Birmingham

Delivering precision medicine requires more than sophisticated technologies or increasingly complex datasets. Understanding individual patients, particularly those with complex diseases and post-infectious syndromes, demands integration of genomic, molecular, clinical, environmental, and longitudinal information. This presentation explores how connecting fragmented expertise, data, and computational capabilities can bridge the gaps between discovery, biological understanding, and clinical action, advancing a more collaborative, integrated approach to individualized diagnosis and treatment.


Register

Conference Tracks

T1: Data Platforms & Storage Infrastructure